Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2633 • ACR Convergence 2025
Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
Hsin-Hua Chen, Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China)
Background/Purpose: To compare safety outcomes in patients with ankylosing spondylitis (AS) initiating Janus kinase inhibitors (JAKi) versus tumor necrosis factor inhibitors (TNFi).Methods: This retrospective cohort…
Abstract Number: 2321 • ACR Convergence 2025
Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
Martín Valdez-López¹, Ana Barrera-Vargas¹, Javier Merayo-Chalico², Irazú Contreras-Yañez³, Carlos Abdiel Abitia Borboa⁴, Iris Paola García-Herrera¹, Raúl Pérez-Gamboa¹ and Guillermo Arturo Guaracha-Basáñez¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Distrito Federal, Mexico, ²Reumátika, Centro de Vanguardia en Reumatología, Ciudad de México, Federal District, Mexico, ³Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Mexico, ⁴Universidad Autónoma de Sinaloa Facultad de Medicina Culiacán, Culiacan, Sinaloa, Mexico
Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…
Abstract Number: 1450 • ACR Convergence 2025
The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Patrick-Pascal Strunz¹, Tobias Heusinger², Maxime Le Maire², Anna Fleischer³, Karsten Sebastian Luetkens⁴, Patricia Possler², Michael Gernert¹, Hannah Labinsky⁵, Robert Leppich⁶, Astrid Schmieder⁷, Ludwig Hammel⁸, Billy Sperlich⁹, Matthias Fröhlich¹ and Marc Schmalzing¹⁰, ¹University Hospital of Wuerzburg, Department of Medicine II, Rheumatology/ Immunology, Wuerzburg, Germany, ²University of Wuerzburg, Wuerzburg, Germany, ³University Hospital of Wuerzburg, Department of Medicine II, Psychosomatics, Wuerzburg, Germany, ⁴University Hospital of Wuerzburg, Institute of Diagnostic and Interventional Radiology, Wuerzburg, Germany, ⁵University Hospital of Wuerzburg, Würzburg, Germany, ⁶University Hospital of Wuerzburg, Chair of Software Engineering (Informatik II), Department of Computer Science, Wuerzburg, Germany, ⁷University Hospital Würzburg, Department of Dermatology, Venereology, and Allergology, Wuerzburg, Germany, ⁸Deutsche Vereinigung Morbus Bechterew e. V., Schweinfurt, Germany, ⁹Integrative and Experimental Exercise Science and Training, Institute for Sports Science, Wuerzburg, Germany, ¹⁰Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany
Background/Purpose: Axia is a novel digital therapeutic (DTx) specifically designed for patients with axial spondyloarthritis (axSpA), in compliance with the European Medical Device Regulation (MDR).…
Abstract Number: 1332 • ACR Convergence 2025
Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Gilad Halpert¹, Yair Dankner², Eri Govrin¹, Abdulla Watad³, Omer Gendelman¹, Shlomo Segev¹, Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Shenkar College of Engineering and Design, Ramar Gan, Israel, ³Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: Spectral analysis of liquid biopsies has recently emerged as a promising, non-invasive approach to improve the diagnosis of various pathologies. Our objective was to…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 2583 • ACR Convergence 2025
CCL20+ monocytes expanded by HLA-B*27 fuel Th17 generation in Axial Spondyloarthritis
Jinyi Zhao¹, Feng Liu², Hui Shi³, Liye Chen¹ and Paul Bowness⁴, ¹Botnar Research Center, University of Oxford, Oxford, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Botnar Research Center, University of Oxford, Oxford, England, United Kingdom, ⁴NIHR Oxford Biomedical Research Centre, University of Oxford, NDORMS, Oxford, United Kingdom
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory arthritis characterized by monocyte activation and Th17 cell expansion. While HLA-B*27 is the strongest genetic risk factor…
Abstract Number: 2315 • ACR Convergence 2025
Alterations in the gut microbiome in ankylosing spondylitis and their correlation with disease activity
Hyemin Jeong¹, Eun-Jung Park² and Chan Hong Jeon¹, ¹Soonchunhyang University Bucheon Hospital, Bucheon, Republic of Korea, ²National Medical Center, Seoul, Republic of Korea
Background/Purpose: The microbiome significantly influences immune dysfunction and gut dysbiosis in patients with ankylosing spondylitis (AS). This study seeks to define the distinct microbial characteristics…
Abstract Number: 1444 • ACR Convergence 2025
Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
Jeffrey Curtis¹, Genevieve Gauthier², Lara Fallon³, David Gruben³, You-Li Ling⁴, Matthew Brouillette³, Arne Yndestad⁵, Yu hong⁶ and Mona Kelkar⁶, ¹Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ²Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, ³Pfizer Inc, New York, NY, USA, New York, ⁴Pfizer Inc, New York, NY, USA, New York, NY, ⁵Pfizer Inc, Oslo, Norway, Oslo, Norway, ⁶Genesis Research Group, Hoboken, NJ, USA, New York
Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…
Abstract Number: 0592 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Julio Ramírez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Rajan Bajracharya¹², Patrik Öhagen¹³, Christine de La Loge¹⁰ and William Tillett¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Slough, England, United Kingdom, ¹³UCB, Stockholm, Sweden, ¹⁴Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal…
Abstract Number: 0526 • ACR Convergence 2025
Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
Chang-Nam Son¹, Dong-Ki Jang², So-Hye Nam³, Yoon-Jeong Oh⁴, Sungsin Jo⁵, Jong-Seo Kim⁶ and Tae-Hwan Kim⁷, ¹UIJEONGBU EULJI MEDICAL CENTER, EULJI UNIVERSITY, UIJEONGBU, Republic of Korea, ²School of Biological Sciences, Seoul National University, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu, Republic of Korea, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea, ⁵Department of Biology, Soonchunhyang University, Asan,, Republic of Korea, ⁶School of Biological Sciences, Seoul National University, Seoul, ⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Currently available diagnostic tests for inflammatory arthritis lack sufficient sensitivity and specificity, often requiring the integration of clinical manifestations with physician expertise for accurate…
Abstract Number: 2560 • ACR Convergence 2025
Quality and Accuracy of TikTok Videos on Axial Spondyloarthritis: A Modified DISCERN Analysis
Mahiar Rabie and Susan Harwell, University of Tennessee- Nashville, Nashville, TN
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease of the axial skeleton that can cause significant pain and disability. Its variable and often non-specific…
Abstract Number: 2035 • ACR Convergence 2025
Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease
Joshua Friedman¹, JD Lu², Bing Wang², Kinjal Hew², Preeyam Patel², Michael Kennedy², Mark Rose², Curtis Sheldon², Rachel McLean², Emily Svejnoha², MiRa Huyghe¹, Brian Connolly² and Deanna Nguyen², ¹Spyre Therapeutics, Waltham, MA, ²Spyre Therapeutics, Waltham
Background/Purpose: TL1A is an inflammatory cytokine and a member of the TNF superfamily. Target cells that express DR3 and respond to TL1A include T cells,…
Abstract Number: 1445 • ACR Convergence 2025
Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Jessica A. Walsh¹, Abhijeet Danve², Isabel Truman³, Dan Twigg³, Hervé Besson⁴ and Helena Roque⁵, ¹Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, ³Adelphi Real World, Bollington, United Kingdom, ⁴UCB, Breda, Netherlands, ⁵UCB, Brussels, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition affecting the sacroiliac joints and spine.1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits…
Abstract Number: 0570 • ACR Convergence 2025
Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Gilad Halpert¹, Eri Govrin¹, Omer Gendelman¹, Abdulla Watad², Yehuda Shoenfeld¹ and Howard Amital¹, ¹Sheba Medical Center, Ramat Gan, Israel, ²Tel Hashomer Medical Center, Ramat Gan, Israel
Background/Purpose: A substantial number of patients with rheumatic inflammatory/autoimmune diseases, do not achieve adequate symptom control with current standard-of-care therapies, including biologics. The endocannabinoid system…
Abstract Number: 0524 • ACR Convergence 2025
Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
Esra Erpek¹, Hasan Kocaayan², Elif Ediboğlu³, Ayberk Sinci⁴, Özgür Tosun⁴, Dilek Solmaz³ and Servet Akar⁵, ¹İzmir Katip Çelebi Üniversitesi, Romatoloji Bilim Dalı, İzmir, Izmir, Turkey, ²Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Turkey, ³Izmir Katip Çelebi University School of Medicine, Rheumatology, Turkey, İzmir, Izmir, Turkey, ⁴İzmir Katip Çelebi Üniversitesi, Radyoloji Bilim Dalı, İzmir, Izmir, Turkey, ⁵Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey
Background/Purpose: This study aimed to assess the rate of progression in sacroiliac joints in non-radiographic axial spondyloarthritis (nr-axSpA) and to identify the predictive factors for…

1
2
3
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].